drugset
drugset / Trial / NCT06109558

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

NCT06109558 ↗

Phase 1/2 Recruiting 120 enrolled Hunan Province Tumor Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, single-arm, dose-escalation, multicenter phase I/II clinical trial. The primary endpoints of this study were to evaluated the safety, tolerability, pharmacokinetic profile and preliminary efficacy of HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy. The secondary endpoints of this study were to evaluated the efficacy HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy.

Timeline

Start
2023-12-31
Primary completion
2026-12-30
Completion
2027-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject LMV-12 Unknown 30 mg —
Subject LMV-12 Unknown 60 mg —
Background Osimertinib Small molecule 80 mg —

Indications

non-small cell lung carcinoma